{"id":11053,"date":"2024-02-13T12:00:34","date_gmt":"2024-02-13T17:00:34","guid":{"rendered":"https:\/\/www.med.unc.edu\/urology\/?p=11053"},"modified":"2024-03-06T14:59:54","modified_gmt":"2024-03-06T19:59:54","slug":"unc-urology-participates-in-cutting-edge-clinical-trial-of-potential-new-combination-therapy-for-bladder-cancer","status":"publish","type":"post","link":"https:\/\/www.med.unc.edu\/urology\/unc-urology-participates-in-cutting-edge-clinical-trial-of-potential-new-combination-therapy-for-bladder-cancer\/","title":{"rendered":"ºÚÁÏÍø Urology Participates in Cutting Edge Clinical Trial of Potential New \u201cCombination Therapy\u201d for Bladder Cancer"},"content":{"rendered":"

\"ahead<\/p>\n

\n
Innovative research at ºÚÁÏÍø is helping to explore a potential new treatment for patients with a form of bladder cancer for which current treatment options are limited.<\/p>\n

The term \u201cBCG unresponsive, non-muscle invasive bladder cancer,\u201d refers to a type of cancer that does not respond well to standard treatment, which involves instilling an immunotherapy drug known as BCG (Bacillus Calmette-Guerin) directly into the bladder to attack the tumor.<\/p>\n

While this approach works for many patients, for some it is not effective. Unfortunately, some patients for whom this treatment fails despite multiple rounds of therapy may require a radical cystectomy, or removal of the bladder.<\/p>\n

In an effort to find additional therapeutic options, a multi-center Phase 3 clinical trial named \u201cQUILT\u201d is exploring a potential new treatment that involves administering BCG combined with an experimental drug known as N-803 (Nogapendekin alfa inbakicept), with the goal of providing a synergistic therapeutic effect.<\/p>\n

ºÚÁÏÍø is currently one of the only medical centers in the Southeast U.S. participating in the \u201cQUILT\u201d trial and providing patients with access to the novel drug combination being studied. If approved by the FDA, the new approach could potentially become a new first line treatment for this type of early stage bladder cancer.<\/div>\n

\n

More Reading:<\/strong>
IL-15 Superagonist NAI in BCG-Unresponsive Non\u2013Muscle-Invasive Bladder Cancer<\/a>
NEJM Evidence<\/p>\n<\/div><\/div>\n

Understanding Bladder Cancer Treatment<\/h2>\n

Bladder cancer is typically viewed as a chronic disease that is treated over a period of time, with recurrences requiring periodic additional treatments, according to Dr. Marc Bjurlin<\/a>, lead investigator for the QUILT trial being conducted at ºÚÁÏÍø, and Director of Clinical Trials for ºÚÁÏÍø Urology.<\/p>\n

He is one of a team of ºÚÁÏÍø Urology experts who are exploring the most advanced techniques and therapeutic options to treat patients with bladder cancer, as well as the full range of urologic diseases.<\/p>\n

When cancer cannot be eliminated from the bladder, the primary goals are to<\/p>\n

    \n
  1. Prevent the disease from progressing, and<\/li>\n
  2. Keep it at a level that prevents the need for bladder removal.<\/li>\n<\/ol>\n

    While initial reports regarding the QUILT multi-center clinical trial are promising, patients should address specific questions regarding bladder cancer treatments with their physician to ensure proper context.<\/p>\n

    As of February, 2024 enrollment of new patients into the QUILT trial is wrapping up, and reporting of results for the trial on a nationwide basis is anticipated in the near future. Additional ºÚÁÏÍø trials in the same disease category are opening soon.<\/p>\n

    Ongoing Research and Innovation at ºÚÁÏÍø<\/h2>\n

    The ºÚÁÏÍø Department of Urology is uniquely qualified to conduct advanced clinical research because it has the infrastructure needed to participate in complex clinical trials, offer patients the latest and most novel medications, and provide the supporting technology needed for implementation and results analysis.<\/p>\n